Transcenta Unveils Promising Preclinical Results for Novel Cancer Therapy

Transcenta Holding Limited ( (HK:6628) ) has shared an announcement.

Transcenta Holding Limited announced promising preclinical results for its novel FGFR2b-targeted ADC, TST105, at the AACR Annual Meeting 2025. The ADC demonstrated significantly enhanced anti-tumor activity compared to existing MMAE-based ADCs in gastric and colorectal tumor models. With a novel topoisomerase I inhibitor payload and site-specific conjugation, TST105 showed superior tumor growth inhibition and overall response rates. This advancement positions Transcenta as a potential leader in developing transformative cancer therapies, with plans to advance TST105 into clinical development.

More about Transcenta Holding Limited

Transcenta Holding Limited is a biotechnology company focused on developing innovative therapies for cancer treatment. The company specializes in antibody-drug conjugates (ADCs) targeting specific cancer markers, with a strong emphasis on addressing cancers with high FGFR2b overexpression.

YTD Price Performance: 100.0%

Average Trading Volume: 1,195,787

Technical Sentiment Signal: Buy

Current Market Cap: HK$537.1M

See more data about 6628 stock on TipRanks’ Stock Analysis page.